Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
When it comes to nanoscience, Transmission Electro
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Russia’s Sputnik V vaccine was 91.6 percent effective in preventing people from growing COVID-19, according to peer-reviewed results from its late-stage clinical trial published in The Lancent global clinical journal on February 2.
Scientists said the Phase III trial results meant that the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow’s decision to roll out the vaccine before closing data had been released.
The results, collated by the Gamaleya Institute in Moscow that acquired and tested the vaccine, were in accord with efficacy data reported at earlier stages of the trial, which was running in Moscow since September.
“The Growth of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and a lack of transparency,” Professor Ian Jones of the University of Reading and Professor Polly Roy, of the London School of Hygiene & Tropical Medicine, said in a remark shared by The Lancet.
“However, the outcome reported here is clear and the scientific principle of vaccination is demonstrated,” said the scientists, who weren’t involved in the study. “Another vaccine is now able to join the fight to decrease the prevalence of COVID-19.”
The results were based on data in 19,866 volunteers, of whom a quarter received a placebo, the researchers, led by the Gamaleya Institute’s Denis Logunov, stated in The Lancet.
Since the trial in Moscow started, there were 16 recorded cases of symptomatic COVID-19 among individuals who received the vaccine, and 62 among the placebo group, the scientists stated.
This showed that a two-dose regimen of the vaccine – two shots based on two different adenovirus vectors, administered 21 days apart – was 91.6% effective against symptomatic COVID-19.
Russia had accepted the vaccine in August, before the large scale trial had started, saying it was the first state to do so to get a COVID-19 shot.
